Regulus Therapeutics (NASDAQ:RGLS) shares are expected to touch $25.25 in the short term. This short term price target has been shared by 4 analysts. However, the standard deviation of short term price estimate has been valued at 8.77. The target price could hit $35 on the higher end and $16 on the lower end.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Chardan Capital, maintains their rating on the shares of Regulus Therapeutics (NASDAQ:RGLS). Chardan Capital has a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $20 per share from a prior target of $15. The rating by the firm was issued on June 7, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the COO of Regulus Therapeutics Inc., Hagan Joseph P had purchased shares worth of $71,900 in a transaction dated on March 3, 2016. A total of 10,000 shares were purchased at a price of $7.19 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Regulus Therapeutics (NASDAQ:RGLS) : On Monday heightened volatility was witnessed in Regulus Therapeutics (NASDAQ:RGLS) which led to swings in the share price. The stock opened for trading at $5.21 and hit $5.51 on the upside , eventually ending the session at $5.46, with a gain of 3.61% or 0.19 points. The heightened volatility saw the trading volume jump to 1,032,507 shares. The 52-week high of the share price is $11.59 and the company has a market cap of $288 million. The 52-week low of the share price is at $4.96 .
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Companys Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.